Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-299

I thought HER-Vaxx's commercial application was to improve cancer patient being treated with Chemotherapy which was used in combination with other drug treatment and not go directly head to head with the drug treatment like Herceptin and from the last clinical update released for HER-Vaxx, the efficacy was very good which was why the pps rerated from 15c to 30c. I still recall @slick questioning this announcement very early in the morning and other posters telling him to stick to charting lol, did your mate ask you to look at that clinical trial update???

I still see a big market for HER-Vaxx but will need further clinical trial data and clearly it isn't the highest priority of the IP right now which is understandable as the others have taken higher priority due to their excellent clinical trial data and much bigger market potential.